APUS
Financials
- Market Capitalization 5.86 M
- Employee 7
- Founded 2020
- CEO N/A
- Website www.apimedsus.com
- Headquarter Delaware, United States
- FIGI BBG01Q0T3D78
- Industry Drug Manufacturers—General
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 4586 |  QCLS Q/C Technologies, Inc. - Common Stock | 2.35 USD | -0.84% | -7.84% | -6.37% | -47.78% | 19.25 M USD | ||
| 4636 |  MDCX Medicus Pharma Ltd. - Common Stock | 0.26 USD | -3.70% | -3.70% | 0.00% | -77.97% | 16.43 M USD | ||
| 4899 |  KAPA Kairos Pharma, Ltd. Common Stock | 0.24 USD | 0.00% | 0.00% | -17.24% | -58.62% | 5.69 M USD | ||
| 4966 |  VIVS VivoSim Labs, Inc. - Common Stock | 0.29 USD | 0.00% | +3.57% | -14.71% | -84.82% | 4.31 M USD |
Frequently asked questions about Apimeds Pharmaceuticals US, Inc.
What is the Apimeds Pharmaceuticals US, Inc. stock price today?
The current price of Apimeds Pharmaceuticals US, Inc. (APUS) is 3.88. Over the past 24 hours, the stock has changed by -0.51%. Follow the APUS chart for real-time price dynamics.
What is the stock ticker of Apimeds Pharmaceuticals US, Inc.?
Apimeds Pharmaceuticals US, Inc. trades under the ticker APUS. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Apimeds Pharmaceuticals US, Inc. stock going up?
APUS has changed by -13.78% over the last week, -29.07% over the last month, and +196.18% over the last year. Review the chart to see whether the current move is part of a broader trend.
What is the market capitalization of Apimeds Pharmaceuticals US, Inc.?
Apimeds Pharmaceuticals US, Inc. currently has a market capitalization of 5.86 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.
What were Apimeds Pharmaceuticals US, Inc. earnings last quarter?
Last quarter, Apimeds Pharmaceuticals US, Inc. reported earnings of -11.77 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.
What was Apimeds Pharmaceuticals US, Inc. revenue for the last quarter?
Apimeds Pharmaceuticals US, Inc. reported quarterly revenue of 283.45 K. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.
What was Apimeds Pharmaceuticals US, Inc. net income for the last quarter?
Apimeds Pharmaceuticals US, Inc. reported net income of -20.17 M for the last quarter. The previous quarter showed -35.06 M, which means net income changed by +42.46%.
How many employees does Apimeds Pharmaceuticals US, Inc. have?
As of the latest available data, Apimeds Pharmaceuticals US, Inc. has 7 employees. Workforce size can provide additional context about the company's scale and operations.
What is Apimeds Pharmaceuticals US, Inc. EBITDA?
Apimeds Pharmaceuticals US, Inc. EBITDA is -5.99 M, and its EBITDA margin is -2 113.5%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Apimeds Pharmaceuticals US, Inc. stock?
You can buy Apimeds Pharmaceuticals US, Inc. (APUS) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Apimeds Pharmaceuticals US, Inc. stock?
Investing in Apimeds Pharmaceuticals US, Inc. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the APUS chart and related analysis on metatrader.com as part of your research.